Tumors are known to establish an immunosuppressive tumor microenvironment (TME) that prevents CD8 T cells from killing tumor cells. Administration of attenuated bacteria directly into tumor sites is known to promote inflammation and improve tumor control. Our lab has developed a method termed ReACT (Reenergized Adoptive Cell Transfer) in which tumor–reactive CD8 T cells are transduced with a chimeric antigen receptor (CAR) specific for a bacterial antigen. Co–administration of these modified T cells and bacteria into the tumor site significantly improves tumor control compared to standard CAR T cells or bacterial injection alone. We are currently working on advancing and improving this technology to advance treatment for solid tumors.